MarginsXMarginsX
Home › Markets › Health Care › VTRS

Viatris Inc. (VTRS)

VTRS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$20.74
-0.38% on the day
Market cap
$23.8B
Large cap
Revenue · 2025
$14.3B
-3.0% on 2024
Net income · 2025
-$3.5B
-24.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/0001792044-26-000013-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVTRS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001792044
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$14.3B
Net income-$3.5B
Operating income-$2.7B
Net margin-24.6%
Operating margin-18.6%
Revenue growth-3.0%
Cash$1.3B
Total assets$37.2B
P/E (computed)Net income was not positive
P/S (computed)1.7×

Warning signs

Cash runway
Cash-flow positive
$1.8B cash at September 30, 2026
Share count, 1 year
-0.5%
2025-11-03 to 2026-11-02 · -4.4% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$1.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$1.8B cash; operating cash flow $621.3M a quarter.Report 2026-09-30
Shares outstanding1,146,454,729 (2026-11-02); 1,151,769,872 a year earlier; 1,199,671,000 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Pittsburgh, Pennsylvania, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $2K, sold $1.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$3.7B-$325.3M$899.4M$1.8B$13.3B$14.7B10-Q 2026-11-05
Q2 2026
2026-06-30
$3.8B-$118.8M$381.8M$886.5M$13.4B$14.7B10-Q 2026-08-06
Q1 2026
2026-03-31
$3.5B$176.4M$388.3M$1.8B$14.3B$14.6B10-Q 2026-05-07
Q4 2025
2025-12-31
$3.7BNot filed$815.8M$1.3B$14.4B$14.3B10-K 2026-02-26
Q3 2025
2025-09-30
$3.8B-$128.2M$744.9M$975.3M$14.4B$14.1B10-Q 2026-11-05
Q2 2025
2025-06-30
$3.6B-$4.6M$219.7M$566.4M$14.5B$14.1B10-Q 2026-08-06
Q1 2025
2025-03-31
$3.3B-$3.0B$535.5M$755.0M$14.2B$14.3B10-Q 2026-05-07
Q4 2024
2024-12-31
$3.5BNot filed$482.7M$734.8M$14.0B$14.7B10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-15
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-02

Source: SEC EDGAR submissions feed, 547 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.6%
1 month+20.7%
3 months+29.8%
Year to date+67.2%
1 year+90.8%
From 52-week high-1.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
UTHRUnited Therapeutics Corporation$587.88-0.56%$25.0B
ALNYAlnylam Pharmaceuticals Inc.$159.73-3.22%$21.4B
INSMInsmed Incorporated$122.88+1.42%$27.0B
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
ASNDAscendis Pharma A/S Ordinary Share$271.73-1.33%$17.9B
GMABGenmab A/S ADS$51.57+0.39%$32.2B
ZTSZoetis Inc.$84.39+0.68%$34.3B
JAZZJazz Pharmaceuticals plc Common Stock (Ireland)$239.77-0.74%$15.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier